- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03466866
Reducing Emergency Diabetes Care for Older African Americans (PREVENT)
Randomized Controlled Trial of Preventing and Reducing Emergency Visits in Diabetes Through Education and Telehealth vs. Diabetes Education to Reduce Emergency Visits and Hospitalizations Over 12 Months in African Americans Americans
This RCT will compare the efficacy of Preventing and Reducing Emergency Visits in Diabetes through Education and Trust (PREVENT) vs. intensive home-based diabetes (DM) education [i.e., Enhanced Usual Care (EUC)] to reduce DM-related emergency department (ED) visits and/or hospitalizations over 12 months (primary outcome) in 230 blacks with diabetes, 50 years and older, after an ED visit. A moderation analysis will determine whether participants who reside in low- vs. high-need communities [defined by Community Need Index scores (i.e., an indicator of the built environment)] respond differently to treatment.
PREVENT is a collaborative intervention of Primary Care Physicians, (PCPs), a DM nurse educator, and Community Health Workers (CHWs) that extends from the ED into the community. The CHWs will: 1) deliver in-home DM education to increase participants' knowledge and skills to manage DM; 2) use DM-specific Behavioral Activation to reinforce DM self-care; and 3) facilitate telehealth visits with PCPs and a DM nurse educator to increase access to care. The control treatment, EUC, is home-based intensive DM education. EUC matches PREVENT in treatment intensity (i.e., number and duration of in-home visits) and delivery of DM self-care education, but does not include PREVENTS's other active elements (i.e., Behavioral Activation and telehealth). The treatment comparison will identify PREVENTS's specific efficacy over and above EUC. We hypothesize that PREVENT will halve the rate of incident DM-related ED visits and/or hospitalizations relative to EUC. The three secondary outcomes are: 1) subjective perceptions of access to care; 2) receipt of DM Quality Metrics (i.e., objective indicators of realized access to care); and 3) DM self-care.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This Phase-III RCT will compare the efficacy of Preventing and Reducing Emergency Visits in Diabetes through Education and Trust (PREVENT) vs. intensive home-based DM education to reduce the number of DM-related ED visits and/or hospitalizations over 12 months (primary outcome), in 230 AAs with DM, 40 years and older, who are recruited from the ED after an ED visit. PREVENT is a culturally relevant intervention that extends from the ED to the community, and aims to improve access to care and DM self-care (secondary outcomes). A mediation analysis will determine whether changes in access to care and/or DM self-care explain PREVENT's efficacy. A moderation analysis will determine whether participants who reside in low- vs. high-need communities [defined by Community Need Index scores (i.e., an indicator of the built environment)] respond differently to treatment.
PREVENT will begin soon after the participant's index ED visit, when many patients remain uncertain how to manage DM or how to access follow-up care. Community Health Workers (CHWs), who are race-concordant with participants, will: 1) deliver in-home DM education to increase participants' knowledge and skills; 2) use DM-specific Behavioral Activation to improve DM self-care; and 3) facilitate telehealth visits with the participant's primary care physician (PCP) and a DM nurse educator to increase access to care. The control treatment, EUC, is intensive home-based DM education. EUC matches PREVENT in treatment intensity (i.e., 6 in-home sessions over 4 months, and 3 booster sessions over the next 8 months) and delivery of culturally relevant DM education, but does not include DM-specific Behavioral Activation or telehealth visits. The treatment comparison will identify PREVENT's specific efficacy over and above EUC.
This RCT is significant as the population ages and becomes more racially diverse, and as ED use and costs increase. This RCT is innovative because it: 1) tests the first ED-to-community intervention designed to reduce the need for ED care in AAs with DM; 2) assesses both subjective and objective indicators of access to care; and 3) defines the specific characteristics of COPDE that confer its cultural relevance. If successful, PREVENT will meet Healthy People 2020's twin goals of reducing the personal and societal costs of DM and achieving health equity for all Americans. The Specific Aims of this RCT are:
Primary Specific Aim: Test the efficacy of PREVENT to reduce the number of incident DM-related ED visits and/or hospitalizations over 12 months (primary outcome) in AAs with DM. Hypothesis: PREVENT will halve the number of incident DM-related ED visits and/or hospitalizations relative to EUC over 12 months.
The Secondary Aims are to:
- Test the efficacy of PREVENT to increase perceived access to care over 12 months (secondary outcome). Hypothesis: PREVENT will increase Patient Satisfaction Questionnaire-18 scores to a greater extent than EUC over 12 months.
- Test the efficacy of PREVENT to increase realized access to care over 12 months (secondary outcome). Hypothesis: PREVENT will increase the number of received Diabetes Quality Metrics (e.g., hemoglobin A1c testing, urine screening) to a greater extent than EUC over 12 months.
- Test the efficacy of PREVENT to improve DM self-care over 12 months (secondary outcome). Hypothesis: PREVENT will increase Diabetes Self-Care Inventory scores to a greater extent than EUC over 12 months.
- Determine if increasing subjective and/or objective indicators of access to care and/or DM self-care mediates PREVENT's reduction of DM-related ED visits and/or hospitalizations. Hypothesis: PREVENT will reduce DM-related ED visits and/or hospitalizations to the extent that it increases subjective and/or objective indicators of access to care and/or improves DM self-care.
The Exploratory Aims are to: 1) determine whether PREVENT reduces "all cause" ED visits/hospitalizations relative to EUC.; 2) determine whether Community Need Index scores, literacy, age, and/or sex moderate treatment effects; 3) determine if PREVENT improves glycemic control (i.e., lowers hemoglobin A1c levels), impacts DM-related health beliefs, reduces depression, and/or improves quality-of-life; 4) identify PREVENT's treatment features that confer its cultural relevance; and 5) estimate PREVENT's costs and net financial benefit to the healthcare system.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19107
- Thomas Jefferson University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- African American race (self-identified)
- Age ≥ 40 years
- Type 1 or 2 DM
- A DM-related cause for the ED visit in the opinion of the ED physician
- Has a Jefferson PCP (participants receiving PREVENT will have a telehealth visit with their Jefferson PCP).
Exclusion Criteria:
- Medical or psychiatric morbidity (e.g., acute stroke, schizophrenia) that would preclude study participation in the opinion of the ED physician
- Clinically significant cognitive impairment
- Pregnancy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: PREVENT (Preventing and Reducing Emergency Visits in Diabetes through Education and Telehealth)
Community Health Workers (CHWs), who are race-concordant with participants, will: 1) deliver in-home DM education to increase participants' knowledge and skills; 2) use DM-specific Behavioral Activation to improve DM self-care; and 3) facilitate telehealth visits with the participant's primary care physician (PCP) and a DM nurse educator to increase access to care.
|
Community Health Workers (CHWs), who are race-concordant with participants, will: 1) deliver in-home DM education to increase participants' knowledge and skills; 2) use DM-specific Behavioral Activation to improve DM self-care; and 3) facilitate telehealth visits with the participant's primary care physician (PCP) and a DM nurse educator to increase access to care.
Other Names:
|
|
Active Comparator: EUC (Enhanced Usual Care)
In-home diabetes education with no goal setting or telehealth visits
|
In-home diabetes education with no goal setting or telehealth visits
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Incident Diabetes-related ED Visits and/or Hospitalizations
Time Frame: 12 months
|
The primary efficacy analysis will consider the number of incident diabetes-related ED visits and/or hospitalizations (i.e., an "event") over 12 months after the index ED visit.
Each ED visit or hospitalization is counted as a single event (although an ED visit that leads to a hospitalization is counted once).
ED visits and hospitalization will be ascertained through chart reviews and subject self-report.
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Perceived Access to Health Care
Time Frame: 12 months
|
Patient Satisfaction Questionnaire scores: Mean change from baseline to 12 months.
There are seven subscales, and subscale scores range from 1 to 5 with higher scores indicating greater satisfaction.
|
12 months
|
|
Actual Access to Care
Time Frame: 12 months
|
Number of received Diabetes Quality Metrics (e.g., hemoglobin A1c testing, urine screening) by 12 months.
The metrics are at least 2 HbA1c tests, 1 lipid test, 1 blood pressure check, 1 diabetes foot exam, and 1 dilated fundus examination.
Scores range from 0 to 6, with 6 indicating better access to care.
|
12 months
|
|
Change From Baseline to 12 Months on Diabetes Self-Care Inventory Scores
Time Frame: 12 months
|
Frequency of engaging in diabetes self-care behaviors; Scores range from 0 to 100 with higher scores indicating more frequent engagement in diabetes self-management behaviors.
|
12 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Barry W Rovner, Thomas Jefferson University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- R01DK114033-01A1 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus
-
Guang NingRecruitingType 2 Diabetes Mellitus | Type1 Diabetes Mellitus | Monogenetic Diabetes | Pancreatogenic Diabetes | Drug-Induced Diabetes Mellitus | Other Forms of Diabetes MellitusChina
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
Meir Medical CenterCompletedDiabetes Mellitus Type 2 | Diabetes Mellitus, Non-insulin Dependant | Diabetes Mellitus, on Oral Hypoglycemic Treatment | Adult Type Diabetes MellitusIsrael
-
Peking Union Medical College HospitalUnknownType 2 Diabetes Mellitus | Type 1 Diabetes Mellitus | Gestational Diabetes Mellitus | Pancreatogenic Diabetes Mellitus | Pregestational Diabetes Mellitus | Diabetes Patients in Perioperative PeriodChina
-
State University of New York at BuffaloMedical University of South Carolina; National Institute of Diabetes and Digestive...CompletedDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type II | Diabetes Mellitus, Adult-Onset | Diabetes Mellitus, Non-Insulin-Dependent | Diabetes Mellitus, Noninsulin DependentUnited States
-
State University of New York at BuffaloNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type II | Diabetes Mellitus, Adult-Onset | Diabetes Mellitus, Non-Insulin-Dependent | Diabetes Mellitus, Noninsulin DependentUnited States
-
State University of New York at BuffaloMedical University of South CarolinaCompletedDiabetes Mellitus | Type 2 Diabetes Mellitus | Adult-Onset Diabetes Mellitus | Non-Insulin-Dependent Diabetes Mellitus | Noninsulin Dependent Diabetes Mellitus, Type IIUnited States
-
Hanmi Pharmaceutical Company LimitedUnknownType2 Diabetes Mellitus | Type1 Diabetes MellitusUnited States
-
Leiden University Medical CenterAndaluz Health ServiceCompletedDiabetes Mellitus | Health Behavior | Self Efficacy | Type2 Diabetes Mellitus | Type1 Diabetes MellitusNetherlands, Spain
-
Medtronic MiniMed, Inc.RecruitingType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States, Australia, New Zealand
Clinical Trials on PREVENT
-
Weill Medical College of Cornell UniversityNational Institute of Mental Health (NIMH)RecruitingDepression | Suicidal Ideation | Suicide, AttemptedUnited States
-
University of UtahNational Cancer Institute (NCI); Kaiser Permanente; University of Arizona; Sea...Active, not recruitingHPV Vaccination | Uptake Vaccination | Series CompletionUnited States
-
Omada Health, Inc.University of Southern California; California HealthCare Foundation; Kresge FoundationCompletedObesity | Overweight | PrediabetesUnited States
-
McMaster UniversityRecruitingOsteoporosis | Fracture | Fractures, HipCanada
-
McMaster UniversityHamilton Health Sciences CorporationCompletedFrailty | Osteoporosis | Fracture | Chronic Conditions, MultipleCanada
-
Istanbul Saglik Bilimleri UniversityNot yet recruitingDelirium | Copd | Nurse's Role
-
Marilyn MacKay-LyonsCanadian Institutes of Health Research (CIHR); Heart and Stroke Foundation... and other collaboratorsCompletedTransient Ischemic Attack | Non-disabling StrokeCanada
-
University of LouisvilleCompleted
-
Washington University School of MedicineMissouri Highlands Health CareRecruitingCardiovascular Diseases | ObesityUnited States
-
University of UtahNational Cancer Institute (NCI); Kaiser Permanente; University of Arizona; Sea...CompletedHPV Vaccination | Uptake Vaccination | Series CompletionUnited States